e-learning
resources
Stockholm 2007
Sunday 16.09.2007
Novel therapeutic targets and disease markers in pulmonary pathology
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Metabonomic approach for noninvasive diagnosis of inflammatory lung diseases through nuclear magnetic resonance analysis of exhaled breath condensate
S. Heili-Frades, G. Peces-Barba, M. J. Rodriguez-Nieto, P. Villa-Valverde, D. Castejón, S. Perez-Rial, N. Hernandez, L. Del Puerto-Nevado, L. Martinez-Galan, J. Ruiz-Cabello, N. González-Mangado (Madrid, Spain)
Source:
Annual Congress 2007 - Novel therapeutic targets and disease markers in pulmonary pathology
Session:
Novel therapeutic targets and disease markers in pulmonary pathology
Session type:
Oral Presentation
Number:
409
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Heili-Frades, G. Peces-Barba, M. J. Rodriguez-Nieto, P. Villa-Valverde, D. Castejón, S. Perez-Rial, N. Hernandez, L. Del Puerto-Nevado, L. Martinez-Galan, J. Ruiz-Cabello, N. González-Mangado (Madrid, Spain). Metabonomic approach for noninvasive diagnosis of inflammatory lung diseases through nuclear magnetic resonance analysis of exhaled breath condensate. Eur Respir J 2007; 30: Suppl. 51, 409
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Metabonomic analysis of exhaled breath condensate in adults by nuclear magnetic resonance spectroscopy
Source: Eur Respir J 2008; 32: 1175-1183
Year: 2008
Metabolomic analysis by nuclear magnetic resonance spectroscopy of exhaled breath condensate in patients with cystic fibrosis
Source: Annual Congress 2009 - Cystic fibrosis: understanding a complex disease
Year: 2009
Metabolomic signatures in nuclear magnetic resonance spectra of exhaled breath condensate identify asthma
Source: Eur Respir J 2012; 39: 500-502
Year: 2012
Methodological aspects of nuclear magnetic resonance spectroscopy of exhaled breath condensate
Source: Annual Congress 2011 - Bronchial hyperresponsiveness and exhaled and sputum biomarkers
Year: 2011
Nuclear magnetic resonance-based metabolomics of exhaled breath condensate: methodological aspects
Source: Eur Respir J 2012; 39: 498-500
Year: 2012
Diagnosis of lung diseases based on proteomic analysis of exhaled breath condensate
Source: International Congress 2017 – Clinical problems in lung diseases
Year: 2017
Nuclear magnetic resonance and mass spectrometry analysis of exhaled breath condensate
Source: Annual Congress 2009 - Noninvasive monitoring of airway inflammation: beyond exhaled nitric oxide
Year: 2009
NMR spectroscopy of exhaled breath condensate in the diagnosis of asthma: Validation and reproducibility
Source: Annual Congress 2010 - Exhaled biomarkers: smells like disease
Year: 2010
Metabolomic analysis of exhaled breath condensate in diagnostics of obstructive airway diseases
Source: Annual Congress 2011 - Role of the biomarkers in airway diseases
Year: 2011
Lung disease diagnostic method based on proteomic analysis of exhaled breath condensate
Source: International Congress 2019 – Basic research of airway diseases
Year: 2019
Is the analysis of torbamycin in exhaled breath condensate a diagnostic tool to monitor pulmonary drug deposition?
Source: Eur Respir J 2004; 24: Suppl. 48, 386s
Year: 2004
Exhaled breath condensate sample collection: standards and open issues
Source: Eur Respir Monogr 2010; 49: 152-161
Year: 2010
Exhaled breath analysis by use of eNose technology: a novel diagnostic tool for interstitial lung disease
Source: Eur Respir J, 57 (1) 2002042; 10.1183/13993003.02042-2020
Year: 2021
Prediction of CF exacerbations by FeNO and non-invasive inflammatory markers in exhaled breath condensate
Source: Annual Congress 2008 - Cystic fibrosis: novel aspects of airway function and inflammation
Year: 2008
Correlation between lung function and exhaled breath condensate biomarkers of inflammation in pulmonary diseases
Source: Annual Congress 2009 - Lung function in adults and children
Year: 2009
Differential diagnosis between newly diagnosed asthma and COPD using exhaled breath condensate metabolomics: a pilot study
Source: Eur Respir J, 51 (3) 1701825; 10.1183/13993003.01825-2017
Year: 2018
Metabolomic/proteomic analysis of biomarkers in exhaled breath condensates
Source: Annual Congress 2008 - PG8 - Cellular and molecular technologies of today - treatments of tomorrow
Year: 2008
Exhaled breath condensate biomarkers in COPD
Source: Eur Respir J 2008; 32: 472-486
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept